Compare Charles River Laboratories Intl. Inc (CRL) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Mongodb Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $304.45 (market cap $14.23B), while Mongodb Inc trades at $379.03 (market cap $29.24B). The key difference: Mongodb Inc is far larger — about 2.1× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Mongodb Inc for 45 Days on average.
| CRL | MDB | |
|---|---|---|
Market Cap | $14.23B | $29.24B |
Volume | 1,176,885 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $310.77 | $472.29 |
52-Week Low | $149.93 | $225.95 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $17.06B | $26.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
MongoDB (MDB) trades at $363.03, up 0.64% today, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds with a high P/E of 511.31 and negative net income, though revenue growth remains strong, reaching $2.01B in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
Outlook: Long-term growth potential exists with raised AI-focused targets, but high valuation and profitability challenges pose risks. Analyst consensus is bullish with an $456.76 price target, yet technical indicators and cash flow volatility warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
